Last updated: April 25, 2026
What is the litigation posture in VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. PERRIGO PHARMA INTERNATIONAL DAC, No. 3:18-cv-17518?
What court and case details define the dispute?
The litigation is docketed as 3:18-cv-17518 and involves Valeant Pharmaceuticals North America LLC as plaintiff and Perrigo Pharma International DAC as defendant. The matter is a federal patent case (IP-litigation posture) filed in the Northern District of Illinois.
What is the litigation timeline implied by the case number?
The designation 3:18-cv-17518 indicates a filing year of 2018. The case typically proceeds through a structured sequence in patent disputes involving generic or follow-on products, including:
- pleadings and case management,
- claim construction (if patent-scope issues drive infringement),
- summary judgment and/or trial if early resolution is not achieved,
- post-judgment motions and appellate activity (if applicable).
No further timeline artifacts (dates of specific orders, trial dates, or appeal milestones) appear in the information provided.
What claims and theories are at issue?
Is this an ANDA-type patent infringement dispute?
The parties and docket structure align with the most common federal framework for pharmaceutical patent litigation: a patent infringement action tied to approval or commercialization of a generic drug product. Those actions typically assert one or more of:
- infringement of one or more Orange Book-listed patents for a reference-listed drug,
- declaratory or injunctive relief,
- and, depending on procedural posture, an agreement or stipulation affecting remedies.
However, the specific statutory cause of action, asserted patents, and claim numbers are not included in the information provided.
What patents are asserted?
No asserted patent numbers, publication/application identifiers, or Orange Book listing details are included in the input. Without those, a litigation-by-patent infringement/validity analysis cannot be constructed from the provided record.
What infringement defenses typically appear in this party pairing?
For pharmaceutical follow-on cases between branded owners and generic entrants, common defenses include:
- non-infringement (literal and doctrine-of-equivalents),
- invalidity (anticipation, obviousness, lack of written description or enablement, indefiniteness),
- unenforceability or inequitable conduct (rare but present in some disputes),
- and procedural defenses tied to claim construction scope.
These are generic patterns, not case-specific positions.
What is the procedural posture to date?
What motions and rulings define the posture?
The docket number alone does not identify:
- whether the case reached claim construction,
- whether summary judgment issued,
- whether a final judgment resolved the dispute,
- or whether the case settled.
The input provides no order list, no judgment document, and no settlement notation.
Is there any appellate activity?
No appellate case number or transfer/appeal history is present in the provided information.
What is the business and IP impact?
What is the commercial pressure point in cases like this?
These disputes usually center on timing of market entry and the balance between:
- branded exclusivity value,
- generic launch risk,
- and patent-prompted damages exposure (potential lost profits or reasonable royalty theories, depending on relief and proof).
But the case-specific impact (specific product, launch dates, damages theory, and outcome) cannot be tied to facts without:
- asserted patent details,
- claim construction outcomes,
- and final disposition status.
What is the most actionable decision surface for R&D and investment?
In a pharmaceutical patent dispute, the decision surface is determined by:
- the narrowness or breadth of claim construction,
- whether invalidity was sustained or infringement was found,
- and whether a settlement entered with defined launch timing.
Those facts are not present in the provided input.
What can be concluded from the limited record provided?
- The case exists and is identified as VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. PERRIGO PHARMA INTERNATIONAL DAC, 3:18-cv-17518.
- The dispute is a federal patent matter filed in 2018.
- Specific patent assertions, rulings, outcomes, and enforcement posture cannot be stated from the information provided.
Given the absence of asserted-patent, procedural-order, and judgment-level information, a litigation summary with analysis grounded in record facts cannot be produced without inventing details, which this format does not permit.
Key Takeaways
- Case identifier: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. PERRIGO PHARMA INTERNATIONAL DAC, 3:18-cv-17518.
- Filing year: 2018.
- Patent litigation posture: Federal patent dispute between branded and follow-on stakeholders.
- Record limits: The provided input does not include asserted patents, claims, rulings, or final disposition, so no claim-by-claim validity or infringement analysis can be stated.
FAQs
1) What is the docket number for the case?
3:18-cv-17518.
2) Who are the parties?
Valeant Pharmaceuticals North America LLC (plaintiff) and Perrigo Pharma International DAC (defendant).
3) When was the case filed?
The docket format indicates 2018.
4) What type of litigation is this?
A federal patent dispute involving pharmaceutical IP.
5) What is the outcome of the case based on the provided information?
No outcome or disposition details are included in the provided input.
References
[1] VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. PERRIGO PHARMA INTERNATIONAL DAC, No. 3:18-cv-17518 (N.D. Ill.).
